Cinclus Pharma Holding AB · LS:A3EN5G

Cinclus Pharma Holding AB financial statements

Cinclus Pharma Holding AB's income statement, balance sheet and cash flow, annual and quarterly, each figure dated and linked to the filing it was read from.

Financials

Annual, in SEK

Income statement

LineFY2025FY2024FY2023FY2022
Revenue57.5M4.58M5.96M10.6M
Research and development198.4M136.7M166.7M157.2M
Selling, general and administrative57.2M36.9M39.6M64.1M
Operating income-199.6M-169.6M-201.0M-210.7M
Depreciation and amortization2.38M1.34M1.25M1.11M
EBITDA-197.2M-168.3M-199.7M-209.6M
Interest expense13.9M28.1M17.2M76.0K
Income before tax-183.7M-167.3M-214.6M-231.0M
Net income-184.0M-168.0M-215.1M-249.1M
Earnings per share, basic-3.95-4.54-8.20-5.35
Earnings per share, diluted-3.95-4.54-8.20

Balance sheet

LineFY2025FY2024FY2023FY2022
Cash and equivalents487.3M566.7M88.0M173.5M
Receivables16.1M0
Current assets536.9M600.5M94.1M184.9M
Total assets546.6M601.0M94.4M185.8M
Accounts payable48.5M18.9M16.4M16.9M
Current liabilities136.8M45.5M164.4M46.1M
Total liabilities177.2M45.7M171.2M58.9M
Shareholders' equity369.4M555.3M-76.8M126.9M
Shares outstanding46.5M46.5M46.5M46.5M

Cash flow

LineFY2025FY2024FY2023FY2022
Cash from operations-74.6M-178.4M-209.2M-192.1M
Capital spending-1.13M000
Free cash flow-75.8M-178.4M-209.2M-192.1M
Cash from investing-1.43M0
Cash from financing-1.76M655.2M122.9M
Change in cash-77.8M476.8M-86.3M34.1M